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everolimus-eluting self-expanding stents in the
peripheral vasculature
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Rajeev M. Menon, PhD,g and Lewis B. Schwartz, MD,g Vienna, Austria; Leipzig, Germany; Ghent, Belgium;
Klagenfurt, Austria; Genk, Belgium; and Abbott Park, Ill
Background: A novel self-expanding drug-eluting stent was designed to release everolimus 225 g/cm2 to prevent
restenosis following peripheral arterial intervention. The purpose of this study was to measure the pharmacokinetic
profile of everolimus following stent implantation.
Methods: One hundred four patients with symptomatic peripheral arterial disease underwent implantation of everolimus-
eluting stents in the femoropopliteal arteries. In a prespecified subset of 26 patients, blood samples for assay of everolimus
content were collected prior to stent implantation, at 1, 4, and 8 hours postprocedure, prior to discharge, and at 1 month
postprocedure.
Results: A total of 39 stents, ranging from 28 mm to 100 mm in length, were implanted in 26 patients, resulting in a total
delivered everolimus dose range of 3.0 to 7.6 mg. Following the procedure, the maximum observed everolimus blood
concentrations (Cmax) varied from 1.83 0.05 ng/mL after implantation of a single 80-mm stent to 4.66 1.78 ng/mL
after implantation of two 100-mm stents. The mean time to peak concentration (Tmax) varied from 6.8 hours to 35 hours.
The pharmacokinetics of everolimus were dose-proportional in that dose-normalized Cmax and area under the curve
values were constant over the studied dose range.
Conclusions: After implantation of everolimus-eluting self-expanding stents in the femoropopliteal arteries, systemic
blood concentrations of everolimus are predictable and considerably lower than blood concentrations observed following
safe oral administration of everolimus. (J Vasc Surg 2012;55:400-5.)
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dIntracoronary stents that elute either sirolimus (rapa-
mycin), paclitaxel, everolimus, or zotarolimus have each
been shown to effectively inhibit restenosis in large-scale
clinical trials.1 Their inhibitory effect on restenosis has been
profound, consistently reducing the need for repeat inter-
vention by 50% as compared with bare metal stents.2,3
Although a variety of designs are available, each with their
own unique combination of device, drug, and polymer, the
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400elatively small size of coronary drug-eluting stents (DES)
ssures that their total drug content rarely exceeds 0.2 mg.
his small dose seldom results in substantial systemic expo-
ure to the patient; indeed, pharmacokinetic (PK) studies of
atients treated with coronary DES reveal that the maxi-
um systemic drug concentration observed is typically 2
g/mL, far below accepted limits of pharmacologic safety
or these compounds.4,5
Although efficacious in the coronary vasculature, the
oncept of stent-based drug elution to prevent restenosis
as not been successfully adapted to the peripheral arteries.
he arteries of the periphery, most notably the superficial
emoral artery (SFA), are long and tortuous, with heavy and
omplex plaque burdens typically characterized by multiple
erial stenoses and occlusions. Compared with the coronary
rteries, therefore, intravascular devices designed for the
FAmust be larger, longer, and considerably more flexible.
hey must, by necessity, contain much greater total drug
ontent.
In the SFA TReatment with Drug-Eluting Stents,
STRIDES) clinical trial, a novel self-expanding nitinol
rug-eluting stent system was designed to slowly release
verolimus 225 g/cm2 over a period of several months.
he relatively large diameter and long length of the stent
ecessitated high total drug loads, 4 mg in the longest
evice. The clinical results of the STRIDES trial have
een published elsewhere.6 The purpose of this study
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Volume 55, Number 2 Lammer et al 401was to measure the human PK profile of everolimus up to
1 month following peripheral vascular implantation.
METHODS
Study design and endpoints. The STRIDES trial was
a prospective, nonrandomized, single-arm, multicenter
clinical study designed to evaluate the safety and perfor-
mance of an everolimus-eluting peripheral stent system for
the treatment of atherosclerotic peripheral arterial disease
(PAD). The study was designed to enroll approximately
100 patients with chronic PAD in Rutherford Becker Clin-
ical Categories 2–5 (moderate to severe intermittent clau-
dication, ischemic rest pain, or ischemic ulceration) due to
atherosclerotic de novo or restenotic occlusive lesions of
the SFA or proximal popliteal artery 3 and 17 cm in
length. Stents were available in 28-, 80-, and 100-mm
lengths; the maximum allowable stent length per patient
was 200 mm. Key exclusion criteria included the presence
of an active immunosuppressive disorder, active pharmaco-
logic treatment with known inducers of CYP3A, prior or
planned solid organ transplantation, severe hepatic insuffi-
ciency, or renal insufficiency defined by a serum creatinine
2.5 mg/dL.
In order to assess the human PK profile after everolimus-
eluting self-expanding stent implantation, a subset of clini-
cal sites were selected to participate in a PK substudy of
STRIDES. This substudy is the subject of this article.
The STRIDES PK substudy was conducted in accor-
dance with the International Conference on Harmoniza-
tion (ICH) guidelines-Good Clinical Practices (GCP),
Declaration of Helsinki, ISO 14155-1, ISO 14155-2, and
Ethics Committee requirements. All patients gave written
informed consent for participation.
Drug-eluting stent system. The everolimus-eluting
peripheral stent system is comprised of three components:
the DYNALINK nitinol self-expanding stent, the antipro-
liferative drug everolimus, and an ethylene vinyl alcohol
(EVAL; Kuraray Co, LTD, Osaka, Japan) copolymer.
The DYNALINK .035 Peripheral Self-Expanding
Stent (Abbott Laboratories, Abbott Park, Ill) is con-
structed of binary nickel-titanium, which is superelastic at
body temperature. The 0.008-inch strut thickness design is
based on a series of sinusoidal rings that are connected at six
locations around the circumference such that the connec-
tions are aligned along the length of the stent and posi-
tioned 60 degrees from each other. The safety and efficacy
of the stent system has been examined in several single-arm
and randomized trials of endovascular therapy of PAD.7-11
The antiproliferative drug, everolimus (40-O-(2-
hydroxyethyl)-rapamycin), is a therapeutic agent origi-
nally developed for the prevention of organ transplant
rejection but is also effective at inhibiting the growth of
many solid tumors (CERTICAN, ZORTRESS, AFINI-
TOR; NOVARTIS Pharmaceuticals Corporation, Basel,
Switzerland).12-16 It is a macrolide derivative of rapamycin
(sirolimus) that forms a complex with the cyclophilin
FKBP-12, which binds and inactivates the serine–threonine
kinasemammalian target of rapamycin (mTOR). This com- slex, known as mTORC1, inhibits ribosomal S6 kinase-1
S6K1) and the mRNA cap-binding protein eIF4E, which
re required for efficient translation of certain cell cycle
egulators such as cyclin D1 and ornithine decarboxylase as
ell as transcription factors such as c-MYC and HIF-1.16
ithout these transcription signals, the cell is unable to
ransit from the G1 to S phase, so it is statically arrested.
Oral everolimus is rapidly absorbed with peak concen-
rations achieved in 1 to 2 hours and steady states generated
fter4 days.17 The human half-life and volumes of distri-
ution are 24 to 35 hours and 110 L, respectively.12,18
harmacologically, everolimus has been shown to be safe
nd well-tolerated at systemic therapeutic concentrations
etween 3 and 15 ng/mL.18-20 Approximately 98% of the
rug is metabolized in the liver, so everolimus should be
osed cautiously in patients with hepatic dysfunction.21
Pharmacodynamically, everolimus inhibits vascular
mooth muscle cell proliferation, enhances vascular remod-
ling,13,22,23 and has been shown to be safe and effective as
he drug component of coronary DES.24,25 In the periph-
ral stent system tested herein, the elution of everolimus
as controlled by an EVAL copolymer. EVAL is a semic-
ystalline polymer with a glass transition temperature (Tg)
f 55°C and melting point (Tm) of 180°C. The chemical
ackbone is a C–C bond, and the pendant group is –OH;
either contains hydrolytically or oxidatively labile chemi-
al bonds. Owing to their biocompatibility, EVAL poly-
ers are ubiquitous in medicine. They have been used as
emodialysis and apheresis membranes26-28 and have been
ormulated with dimethyl sulfoxide (DMSO) for use as
mbolic treatment for intracerebral aneurysms and arterio-
enous malformations.29-32
This combination of the DYNALINK nitinol self-
xpanding stent, the antiproliferative drug everolimus,
nd an EVAL copolymer has been referred to as the
DYNALINK-E” stent. The total drug load is 225 g/
m2 stent surface area, a higher dose than coronary
irolimus-eluting (140 g/cm2) or coronary everolimus-
luting stents (100 g/cm2).25,33 The elution profile is
rolonged, with approximately 80% of the drug being
eleased slowly over the first 90 days,34 as opposed to only
0 days in most systems designed for use in the coronary
rteries. For the STRIDES trial, the stent was available in
engths of 28, 80, and 100 mm, with diameters of 6 or 8
m. Given the nominal drug loading specification of 225
g/cm2 stent surface area, and the allowable total stent
ength range of 80 to 200 mm, the total delivered everoli-
us dose ranged from 3.0 to 7.6 mg per patient.
Blood sample collection and disposition. Blood
amples for everolimus assay were collected by venipunc-
ure into 4-mL potassium edetic acid (EDTA) vacutainers.
amples were obtained prior to stent implantation (0 hr), at
pproximately 1, 4, and 8 hours after final stent placement,
efore subject discharge (collection times ranged from
7-166 hours), and at 1 month after discharge from the
tudy site. A total of six blood samples per patient were to
e collected for pharmacokinetic analysis. The frozen blood
amples were shipped from the study site to Eurofins Medi-
r
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February 2012402 Lammer et alnet BV (Breda, the Netherlands) for analysis of everolimus.
Samples were stored frozen at approximately -20°C until
analyzed; a maximum of 260 days elapsed between collec-
tion and analysis, which was within the documented 1-year
stability for everolimus in frozen blood samples.
Whole blood concentration of everolimus was deter-
mined using a validated liquid/liquid extraction high-
performance liquid chromatography (HPLC) method with
tandem mass spectrometric detection (LC-MS/MS). Aco-
mycin was used as an internal standard. The lower limit of
quantitation (LLOQ) for everolimus was 0.2 ng/mL using
a 0.020-mL blood sample. Samples quantified below the
lowest standard were reported as zero. In-study quality
control (QC) samples, supplemented with various concen-
trations of everolimus, were analyzed along with the un-
knowns.
Pharmacokinetic modeling and calculations. Indi-
vidual blood concentrations and the PK parameter values of
everolimus were tabulated for each individual by dose
group. PK parameter values of everolimus were estimated
using noncompartmental methods and the actual sampling
times. These included the maximum observed plasma con-
centration (Cmax) and time to Cmax (Tmax), and the area
under the plasma concentration-time curve (AUC) from
time 0 to 24 hours (AUC0-24) and to the time of the last
measurable concentration (AUC0-last). AUCwas calculated
by linear trapezoidal rule. Dose-normalizedCmax and AUC
values were calculated algebraically by dividing the PK
parameter with the nominal dose. Winnonlin Professional
software (version 5.5; PHARSIGHT Corporation, Moun-
tain View, Calif) was used for calculation of PK parameters.
Data are expressed as mean  standard deviation unless
otherwise noted.
RESULTS
Twenty-six patients were sequentially enrolled from
seven clinical sites in Europe. Their clinical demographics
are given in Table I and are typical for patients with end-
stage PAD. Most lesions were de novo in nature, although
a single patient with restenosis was treated. Themean lesion
length was 9.0  4.4 cm (range, 3.0-17.0 cm); 46% of
Table I. Clinical demographics of the 26 patients
enrolled in the pharmacokinetic subset of the STRIDES
trial
Demographics
Mean  SD or %
of patients
Age (years) 67  11
Male gender 69%
Current or former smoker 77%
Diabetes mellitus 50%
Hypertension 81%
Hypercholesterolemia 88%
Coronary artery disease 58%
Contralateral peripheral vascular disease 77%
Limb salvage indication 15%lesions were totally occluded at the time of intervention. tA total of 39 stents were implanted in 26 patients. A
etrospective evaluation of the stent combinations de-
loyed revealed six unique dose groups, with total im-
lanted stent length ranging from 80 to 200 mm (Table
I). This corresponded to a total everolimus dose range of
.0 to 7.6 mg.
The mean blood concentration-time profiles for all
ose groups (I through VI) are given in Fig 1. Everolimus
elease began immediately after stent implantation as evi-
enced by the appearance of quantifiable whole blood
oncentrations after 1 hour, the first time point measured.
he mean everolimus concentrations generally increased
ith increasing dose and remained relatively flat over the
rst 24 hours. As expected from the polymer design, the
ighest whole blood everolimus levels were generally ob-
erved within the first day, although everolimus remained
etectable in most patients even at 30 days.
Calculated PK parameters for the various doses admin-
stered are provided in Table III. The Cmax varied from
.83  0.05 ng/mL after implantation of a single 80-mm
tent to 4.66  1.78 ng/mL after implantation of two
verlapping 100-mm stents. The AUC0-last varied from 50 to
000 ng · h/mL. The PKs of everolimus were essentially
inear, as illustrated by the relatively similar dose-normalized
max and AUC values over the studied dose range (Fig 2).
ISCUSSION
Given the success of DES at preventing restenosis in the
oronary arteries, many have theorized that this technology
ight also be useful in the peripheral arteries.35-38 The
irolimus-coated self-expanding SMART stent (Cordis, a
ohnson & Johnson Company, Miami Lakes, Fla) remains
he first, and only, peripheral drug-eluting stent to be
ested in clinical trials and reported in the literature.35,39
his device utilized the nitinol SMART stent as its plat-
orm, was loaded with 90-g sirolimus/cm2 stent area
sing a 5- to 10-m copolymer matrix, and delivered its
1-mg drug load (per 80-mm stent) over a period of about
days. A total of 93 patients were enrolled in the combined
IROCCO I and SIROCCO II clinical trials (SIROlimus
oated COrdis SMART nitinol self-expandable stent for
he treatment of obstructive superficial femoral artery dis-
ase). Unfortunately, neither trial achieved its primary end-
oint of a reduction in restenosis and, even after 4 years,
here was no difference in any metric comparing patients
reated with the bare SMART stent versus the sirolimus-
luting stent.38
Despite the disappointing results of the SIROCCO
tudies, two other peripheral DES are currently being
ested in clinical trials. The ZILVER PTX stent (Cook
ncorporated, Bloomington, Ind) is loaded with approxi-
ately 300 g paclitaxel/cm2 stent area.40 Similar to the
CHIEVE coronary stent (Cook) tested in the DELIVER
linical trial (the RX ACHIEVE drug-eluting coronary
tent system in the treatment of patients with De noVo
ativE coronaRy lesions),41 paclitaxel is applied directly to
he ZILVER PTX stent; there is no polymer system serving
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Volume 55, Number 2 Lammer et al 403to control its release. Clinical trial results have not yet been
made available in the scientific literature.
Lastly, an everolimus-eluting nitinol stent has also re-
cently undergone clinical testing and is the subject of this
report. The DYNALINK-E device contains approximately
225 g everolimus/cm2 stent area, which is released slowly
through its incorporation in an EVAL copolymer. The
DYNALINK-E stent was tested clinically in the STRIDES
trial, a prospective, nonrandomized, single-arm, multi-
center clinical study designed to evaluate the safety and
performance of this stent system in patients with atheroscle-
rotic or restenotic PAD. The clinical results of the
STRIDES trial have been published elsewhere.6 The pur-
pose of this communication is to describe the PK results of
STRIDES.
Following the implantation of DYNALINK-E, the
maximum observed everolimus blood concentration (Cmax)
varied from 1.83 0.05 ng/mL after placement of a single
80-mm stent to 4.66 1.78 ng/mL after placement of two
overlapping 100-mm stents. The mean time to peak con-
centration (Tmax) varied from 6.8 hours to 35 hours. The
PK profiles of everolimus released from the stent were
essentially linear, as illustrated by the relatively similar
dose-normalized Cmax and AUC values over the studied
dose range (Fig 2). This is an important safety feature of
drug-eluting systems, that systemic drug concentrations are
predictable and increase in proportion to the total stent
Table II. Dosing scheme of patients enrolled in pharmaco
Dose group Number of patients Stent sizes impl
I 3 80 mm
II 10 100 mm
III 1 28 mm  100
IV 2 80 mm  80 m
V 4 80 mm  100
VI 6 100 mm  10
Total stent length represented as length of first stent  length of second ste
Fig 1. Mean everolimus blood concentration-time profiles after
self-expanding everolimus-eluting stent implantation. Note the
nonlinear nature of the time scale. Data points represent mean 
standard error.length implanted. 0Despite the fact that the peripheral DYNALINK-E
tent contains more than 10 times the amount of drug as
maller coronary DES, the slow elution profile of
YNALINK-E assured that the maximal systemic drug
oncentrations remained modest. For example, the PK
rofiles of the sirolimus-eluting CYPHER stent (Cordis,
ohnson and Johnson; Miami, Fla) were studied in 19
atients and reported in 2006.4 The observed Cmax after
ingle CYPHER stent implantation was 0.57  0.12 ng/
L, which increased to 1.05  0.39 ng/mL after implan-
ation of two stents. This range is only slightly lower than
he range reported herein for the DYNALINK-E stent
1.83-4.66 ng/mL). Similarly, PK results after implanta-
ion of the everolimus-eluting XIENCE V coronary stent
Abbott) are also available.5 The XIENCEV stent is loaded
ith everolimus 100 g/cm2 stent area, somewhat lower
han the sirolimus dose on CYPHER (140 g/cm2) and
onsiderably less than DYNALINK-E (225 g/cm2). In
he XIENCE V PK trial, 39 patients received XIENCE V
tents, resulting in a total everolimus dose range of 53 to
88 g. Mean Cmax values ranged from 0.41  0.16
g/mL (for total stent dose 100 g) to 0.72  0.34
g/mL (100-200 g total dose) to 1.43  0.58 ng/mL
200 g total dose).
Although everolimus Cmax values for patients treated
ith DYNALINK-E are quantitatively similar to everoli-
us and sirolimus concentrations in patients treated with
oronary DES, the high drug content and slow elution of
YNALINK-E naturally resulted in a more sustained sys-
emic PK profile. This was evident in that everolimus could
e detected in low concentrations (1 ng/mL) in most
atients even at the 30-day time point, and the AUC values
or DYNALINK-E far exceeded coronary DES profiles
DYANLINK-E range 50-2000 ng · h/mL compared with
he XIENCE V stent 19-85 ng · h/mL). This was a key
esign feature of DYNALINK-E, that the high total drug
oad would be released slowly, resulting in sustained but
elatively low systemic concentrations.
Furthermore, the observed peak exposure of everoli-
us following implantation of DYNALINK-E stents was
ell below peak concentrations observed in safety studies of
ral everolimus therapy. For example, Neumayer et al
reated cadaveric renal transplant recipients receiving cyclo-
porine A with everolimus in single oral doses ranging from
.25 to 25 mg.42 Peak concentrations ranging from 2.3 
tic subset of the STRIDES trial
Total stent length Total everolimus dose (g)
80 mm 3033
100 mm 3777
128 mm 4847
160 mm 6066
180 mm 6810
200 mm 7554kine
anted
mm
m
mm
0 mm.8 to 179 24 ng/mL were observed, and all dose levels
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treated a similar patient population with oral everolimus in
doses of 0.75 to 10 mg per day for 4 weeks and docu-
mented similar Cmax ranges of 22 to 169 ng/mL.
19 Lastly,
Kovarik et al followed 101 patients receiving daily everoli-
mus in divided doses of 1 to 4 mg for a full year and
documented steady state Cmax levels ranging from 5 to 22
ng/mL.20 Even when combined with other immunosup-
pressants in this difficult patient population, adverse events
such as transient thrombocytopenia and leukopenia were
uncommon. As a result, oral everolimus is available world-
wide as an immunosuppressive adjunct for the prevention
of rejection of transplanted solid organs (Certican, Zor-
tress) and, recently, has been approved in the United States
(Afinitor) as adjunctive chemotherapy for advanced renal
cell carcinoma,43,44 advanced pancreatic neuroendocrine
tumors,45 and subependymal astrocytoma associated with
Table III. Calculated pharmacokinetic parameters of patie
Pharmacokinetic
parameter
Group I
(3.0 mg)
n  3
Group II
(3.8 mg)
n  10
Gr
(4
n
Total stent length 80 mm 100 mm 12
Cmax (ng/mL) 1.83  0.05 2.44  0.61
Cmax/dose
(ng/mL/mg) 0.60  0.02 0.65  0.16
Tmax (h) 18.26  20.02 22.75  22.63
AUC0-24 (ng · h/mL) 36.31  4.76 48.12  13.39
AUC0-24/dose
(ng · h/mL/g) 11.97  1.57 12.74  3.55
AUC0-last
(ng · h/mL) 308.42  293.5 975.9  501.2 5
AUC0-last/dose
(ng · h/mL/g) 101.69  96.77 258.38  132.68 1
AUC0-24, Area under the plasma concentration-time curve from time 0 to 24
the last measurable concentration; Cmax, maximum observed everolimus bl
aNot determined as the last sample time point was 19 hours in these patien
bThe last sample time point was 19 hours in this patient as compared with 
Fig 2. Dose-normalized Cmax versus total everolimus dose in
the STRIDES pharmacokinetic substudy. Treatment with
DYANLINK-E resulted in approximately 0.6 ng/mLwhole blood
concentration per mg of stent-based everolimus implanted. Data
points represent mean  standard deviation.tuberous sclerosis.46In summary, despite the relatively high drug loads
ontained within the DYNALINK-E everolimus-eluting
eripheral self-expanding stent, its implantation is well-
olerated and generates a systemic PK profile well below the
aximum observed whole blood concentrations following
ral everolimus administration.
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